Sales for the first quarter of fiscal year 2027 were 21.448 billion yen, up 10.1% YoY; operating income was 1.95 billion yen, up 28.3% YoY. Ordinary income was 1.432 billion yen, down 13.8% YoY, and net income attributable to owners of the parent was 866 million yen, down 20.6% YoY. Full-year guidance remains as announced, with effects of exchange rate losses considered; performance is expected to proceed as planned.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4559","jir_company_name":"Zeria Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4559-20260806-01.pdf","jir_short_summary":"Sales for the first quarter of fiscal year 2027 were 21.448 billion yen, up 10.1% YoY; operating income was 1.95 billion yen, up 28.3% YoY. Ordinary income was 1.432 billion yen, down 13.8% YoY, and net income attributable to owners of the parent was 866 million yen, down 20.6% YoY. Full-year guidance remains as announced, with effects of exchange rate losses considered; performance is expected to proceed as planned.","jir_summary":"### Summary of Results\nTotal net sales for the first quarter stood at 21,448 million yen, achieving growth year over year. However, ordinary income decreased due to foreign exchange losses. In the segments, the Pharmaceuticals for Medical Use segment remained solid, with progress in product penetration domestically and internationally. Consumer Healthcare contributed from sales growth of the Heparin series. Other businesses declined slightly. There is no change to the full-year outlook at this time.\n\n### Outlook and Capital Position\nFrom the second quarter onward, performance is expected to proceed largely as planned. Considering currency fluctuations, there will be no changes to consolidated earnings projections. Total assets fluctuated, and the equity ratio improved to 61.8%. Reductions in short-term borrowings and decreases in corporate taxes contributed. No additional information on dividend outlook has been disclosed.","jir_financial_highlights":"Net sales: 214,48\u767e\u4e07\u5186 (YoY 10.1% increase)\nOperating income: 19,50\u767e\u4e07\u5186 (YoY 28.3% increase)\nOrdinary income: 14,32\u767e\u4e07\u5186 (YoY \u25b313.8%)\nNet income attributable to owners of the parent: 8,66\u767e\u4e07\u5186 (YoY \u25b320.6%)\nEquity ratio: 61.8% (YoY +1.5%)","jir_category":"","jir_hashtags":"#ZeriaPharmaceutical, #FinancialResults","jir_key_figures":"Net sales: 214,480 million yen (YoY +10.1%)\nOperating income: 19,500 million yen (YoY +28.3%)\nOrdinary income: 14,320 million yen (YoY \u25b313.8%)","jir_meta_title":"Zeria Pharmaceutical Q1 Fiscal Year 2027 Financial Results \u2014 Sales 21.448 billion yen, Operating income 1.95 billion yen, etc.","jir_meta_description":"Key points from Zeria Pharmaceutical's Q1 FY2027 financial results. Net sales of 21.448 billion yen, operating income of 1.95 billion yen, ordinary income decreased due to exchange rate impact. Segment trends and full-year outlook maintained.","jir_og_title":"Zeria Pharmaceutical Announces Q1 Results \u2014 Net Sales 21.448 billion yen","jir_og_description":"Zeria Pharmaceutical's Q1 results show net sales of 21.448 billion yen and operating income of 1.95 billion yen. Ordinary income decreased due to exchange rate impact; full-year outlook unchanged.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9548,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-98106","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n